CDKN2AIPNL

Across TCGA pan-cancer cohorts, CDKN2AIPNL RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated CDKN2AIPNL data layer compared with 5 for mass-spec protein.

The strongest signal is observed in uveal melanoma (UVM), where higher CDKN2AIPNL RNA is associated with worse overall survival. In most high-consensus cancer types, elevated CDKN2AIPNL expression acts as an unfavorable survival marker, although some lineages such as READ and PAAD show a favorable association.

UVM, LIHC, and HNSC are the cancer types where CDKN2AIPNL RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UVM	OS	Median	All	0.422	0.901	<.001	150	view →
LIHC	DFS	Median	All	0.458	0.621	<.001	77	view →
HNSC	DFS	Median	All	0.193	0.472	<.001	66	view →
KIRP	DFS	Median	All	0.862	0.953	.001	54	view →
READ	DFS	Tertile	All	0.928	0.701	.003	47	view →
SCLC	DFS	Median	All	0.140	0.384	.004	40	view →
CESC	OS	Median	IV	0.268	0.789	<.001	40	view →
KICH	DFS	Quartile	II,III,IV	0.375	1.000	.010	30	view →
UCS	DFS	Median	IV	0.440	0.885	.015	30	view →
LUAD	OS	Tertile	All	0.232	0.592	.003	14	view →
MESO	OS	Quartile	All	0.393	0.697	.015	9	view →
PAAD	OS	Median	All	0.470	0.222	.015	8	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

CDKN2AIPNL–UVM (OS)

Open the UVM breakdown →